Institute of General and Ecological Chemistry, Faculty of Chemistry, Lodz University of Technology, Zeromskiego 116, 90-924 Lodz, Poland.
Department of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, Poland.
Molecules. 2022 Apr 22;27(9):2703. doi: 10.3390/molecules27092703.
A novel biologically active thiosemicarbazide derivative ligand () and a series of its five metal(II) complexes, namely: [Co(L)Cl], [Ni(L)Cl(HO)], [Cu(L)Cl(HO)], [Zn(L)Cl] and [Cd(L)Cl(HO)] have been synthesized and thoroughly investigated. The physicochemical characterization of the newly obtained compounds has been performed using appropriate analytical techniques, such as H and C nuclear magnetic resonance (NMR), inductively coupled plasma (ICP), thermogravimetric analysis (TGA), Fourier-transform infrared spectroscopy (FTIR) and magnetic measurements. In order to study the pharmacokinetic profile of the compounds, ADMET analysis was performed. The in vitro studies revealed that the synthesized compounds exhibit potent biological activity against A549 human cancer cell line.
一种新型生物活性硫代卡巴肼衍生物配体 () 及其五种金属(II)配合物,即:[Co(L)Cl]、[Ni(L)Cl(HO)]、[Cu(L)Cl(HO)]、[Zn(L)Cl] 和 [Cd(L)Cl(HO)],已被合成并进行了深入研究。使用适当的分析技术,如 H 和 C 核磁共振(NMR)、电感耦合等离子体(ICP)、热重分析(TGA)、傅里叶变换红外光谱(FTIR)和磁测量,对新获得的化合物进行了物理化学特性的表征。为了研究化合物的药代动力学特征,进行了 ADMET 分析。体外研究表明,合成的化合物对 A549 人癌细胞系表现出很强的生物活性。